Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study
High-dose PIPAC-Ox is feasible and safe. Local and histological response are well identified. However abdominal pain remains a main concern and continuous IV protocols should be considered routinely.
Authors
- Guillaume De Meeus
- V. Kepenekian
- M Pocard
- Olivier Glehen
- Olivia Sgarbura
- Francois Quenet
- Abdelkader Taibi
- Diego A. Zambrano
- Amaniel Kefleyesus
- Alexandru Lintis
- Clarisse Eveno
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Centre Hospitalier Universitaire de Lille (FR)
- Universidad Espíritu Santo (EC)
- Sorbonne Université (FR)
- Hôpital Lyon Sud (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Comisión Honoraria de Lucha contra el cáncer (UY)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Surgical Oncology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1016/j.ejso.2026.111731
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00